Summary
LOS ANGELES--(BUSINESS WIRE)--Cynvenio Biosystems, Inc., the pioneer in LiquidBiopsy technology for the genomic analysis of tumor cells from whole blood in support of cancer precision medicine strategies, announced today the completion a $25.5 million Series B equity financing. Proceeds from the investment will be used to advance the company’s clinical development and commercialization programs. The Series B round was led by Livzon Pharmaceutical Group, Inc., a diversified drug, diagnostics and healthcare company based in Zhuhai, P.R. China. Other investors included Greenwoods Private Equity Funds (Shanghai) and Syno Capital (New York), among others.
Click Here
to read the full article
Click Here
to read the full article